Tirzepatide

GLP-1 / MetabolicResearch Use Only

Also known as: Mounjaro (brand), Zepbound (brand), GIP/GLP-1 dual agonist

The dual-hormone (GLP-1 + GIP) compound in Mounjaro/Zepbound — currently the benchmark for research weight-loss peptides.

Dosing quick reference

research reference

Starting dose

2.5 mg once weekly

Frequency

Once weekly (same day)

Typical range

2.5–15 mg per week

Cycle

12–16+ weeks, stepping up every 4 weeks

Titration (step-up)

Wk 1–4: 2.5 → Wk 5–8: 5 → Wk 9–12: 7.5 → Wk 13–16: 10 mg

Increase only every 4 weeks — GI side effects track the jumps.

Half-life

~5 days

Route

Subcutaneous (research)

Common use

Metabolic and weight-management research

Common vial sizes

5 mg · 10 mg · 15 mg · 30 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Discussed in research as a single-molecule dual agonist; combining with other incretin agents is generally not referenced and would compound gastrointestinal effects.

Reported side effects

NauseaReduced appetiteDiarrheaConstipation

Regulatory note: Prescription drug in Canada and the US; approved for type 2 diabetes and chronic weight management under brand names. Research-grade material is not for human use.

Calculate a dose →Tirzepatide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.